Survodutide vs Retatrutide vs Mazdutide: The Next-Gen GLP-1 Pipeline Compared

Three compounds now define the frontier past first-generation GLP-1 drugs, and all three made the same design bet from different directions: bring the glucagon receptor into a metabolic peptide alongside GLP-1. Retatrutide went furthest, keeping both incretin receptors (GLP-1 and GIP) and adding glucagon as a third arm. Survodutide and mazdutide took the leaner route, each pairing GLP-1 with glucagon alone and leaving GIP out entirely. ^[4]

That makes survodutide and mazdutide close mechanistic cousins, developed independently by different companies on different continents, while retatrutide sits one receptor ahead of both. This is an evidence-first, three-way comparison: mechanism, the trial data behind each compound, side effects, dosing, where each sits in its development pipeline, and who each is right for. Everything here reports what has been published or disclosed about these compounds; none of it is medical advice, and none of the three is approved for human use. We sell retatrutide as a research compound; survodutide and mazdutide are discussed here purely for comparison.

The three compounds at a glance

The single-line version: retatrutide has the most complete receptor coverage and the largest published mean weight loss; survodutide and mazdutide are both leaner dual agonists pursuing the same GLP-1 plus glucagon thesis from separate development programs, one Western and one China-based. The rest of this article is what sits behind each of those columns.

What each compound actually is

Retatrutide, survodutide, and mazdutide are all engineered peptides, not small-molecule drugs, and all three are built to last long enough in the body for once-weekly subcutaneous dosing. Beyond that shared engineering approach, they come from three different companies and three different development histories.

Retatrutide (LY3437943) is developed by Eli Lilly. It is the only compound of the three built as a triple agonist from the start, activating GLP-1, GIP, and glucagon receptors with a single molecule. ^[4] Its Phase 2 program is documented in depth in the complete retatrutide guide.

Survodutide (BI 456906) is developed jointly by Boehringer Ingelheim and Zealand Pharma. It is a dual GLP-1/glucagon agonist built on an oxyntomodulin-like backbone, and it has been studied in parallel obesity and liver-disease (MASH) programs. ^{[2] [3]}

Mazdutide (IBI362, also referenced by the code LY3305677) is developed by Innovent Biologics under license from Eli Lilly, with its clinical program run primarily in China. Like survodutide, it is a dual GLP-1/glucagon agonist rather than a triple agonist. ^[5]

Because survodutide and mazdutide share the same receptor pairing, the meaningful three-way split is not "three different mechanisms." It is one triple agonist (retatrutide) against two independently developed dual agonists (survodutide and mazdutide) that happen to have landed on the same design.

The mechanism: one triple agonist, two dual agonists

All three compounds share the GLP-1 arm, the well-characterized foundation of the entire class: it reduces appetite, slows gastric emptying, and improves glucose handling. All three also share the glucagon arm, the newer and more novel addition to this class. On its own, glucagon raises blood glucose, which is why it seems like an odd choice for a metabolic drug. But paired with sufficient GLP-1 coverage, its useful contribution (increased energy expenditure and lipid mobilization) is retained while the incretin arm offsets the glycemic penalty. ^[4] That is the shared bet behind all three compounds, and it is why all three report liver-fat effects.

The line that separates retatrutide from the other two is GIP. GIP appears to amplify GLP-1's effects rather than act alone, which is widely understood to be why dual GLP-1/GIP agonism (the tirzepatide mechanism) outperformed single-receptor GLP-1 agonism in the first place. ^[4] Retatrutide keeps that amplifier and adds glucagon on top, making it a genuinely three-receptor molecule. Survodutide and mazdutide both leave GIP out, betting that GLP-1 plus glucagon alone is enough, without the added engineering complexity of a third receptor.

This is also a useful moment to place tirzepatide in context, since it is the other prominent dual agonist in the field: tirzepatide pairs GLP-1 with GIP and leaves glucagon out, the mirror image of the survodutide and mazdutide design. Retatrutide is the only compound across all of these that carries all three receptors at once. The full mechanistic breakdown is in how retatrutide works.

The trial data: what each program actually reported

This is the section with the most important caveat in the whole article: none of these three figures come from the same study. Retatrutide, survodutide, and mazdutide each have their own independent Phase 2 program, run in different populations, at different doses, for different durations. There is no published trial that randomized participants to two of these compounds, let alone all three.

Retatrutide's 24.2% figure is the highest published mean weight loss in this comparison, and its response curve had not clearly plateaued by week 48, meaning the true difference at a like-for-like endpoint could be larger still. ^[1] Survodutide's roughly 18.7% at a nearly matched 46-week window is the strongest data point among the two dual agonists reported to a Western regulatory audience so far. ^[2] Mazdutide's Phase 2 program ran over a shorter 24-week primary window in a Chinese population, which limits a direct duration-matched comparison to the other two even before accounting for population differences. ^[5]

The honest framing across all three trials: different sites, different populations, different titration schedules, and in mazdutide's case, a materially shorter trial window. Cross-trial comparisons like this one are a directional signal for where research interest is heading, not a substitute for a head-to-head study, which does not exist for any pair of these three compounds.

Survodutide vs mazdutide: the two dual agonists

Because survodutide and mazdutide share the same receptor pairing, the closest comparison in this article is really between those two, not against retatrutide.

Both compounds are, in effect, parallel bets on the same mechanism, run by different sponsors in different regulatory environments. Survodutide's program has, so far, produced more that is directly verifiable in Western-facing, peer-reviewed literature, including a dedicated MASH trial with histological endpoints. ^[3] Mazdutide's program is comparably active but concentrated in China, and figures from it should be treated as newly emerging and confirmed against primary sources rather than assumed to map cleanly onto Western trial conventions.

Survodutide vs retatrutide: dual vs triple, direct

Retatrutide's clearest one-to-one comparison is against survodutide, since both have substantial published, peer-reviewed Western trial data.

The gap between the two lines up with the receptor that separates them: GIP. Retatrutide keeps it, survodutide does not, and retatrutide's published mean loss is materially higher at a near-matched duration. ^{[1] [2]} Survodutide's counterweight is a purpose-built liver-disease dataset with biopsy-level endpoints, which is arguably the strongest dedicated liver evidence of any compound in this comparison. ^[3] A full breakdown of this pairing lives in the dedicated retatrutide vs survodutide article.

Mazdutide vs retatrutide: the same triple-vs-dual gap, from the other direction

Mazdutide versus retatrutide is structurally the same comparison as survodutide versus retatrutide (dual agonist against triple agonist), just with a different dual agonist and a China-based trial program on the other side of the ledger.

The mechanistic gap is identical: retatrutide keeps GIP, mazdutide does not. ^[4] Retatrutide's published mean weight loss (24.2%) is the higher figure of the two, though mazdutide's shorter 24-week Phase 2 window makes a duration-matched comparison harder to draw cleanly than the survodutide comparison above. ^{[1] [5]} What can be said with more confidence is the receptor logic: adding GIP to a GLP-1/glucagon backbone is retatrutide's central design bet over both dual agonists, and the trial data across all three published programs so far are consistent with that bet paying off, though again, not as a controlled head-to-head finding.

Side effects across all three

All three compounds share the dominant gastrointestinal profile that defines the entire GLP-1 class, and all three add the glucagon-specific effects on top.

The gastrointestinal effects are not incidental; they follow directly from the GLP-1 mechanism all three compounds share. GLP-1 receptor activation slows gastric emptying, which is part of how each compound reduces appetite, and the same slowing is what produces nausea when exposure rises too quickly. That is why the effects concentrate during dose escalation across all three programs and why each uses a stepwise titration schedule rather than starting at a target dose. ^{[1] [2]} None of this is dosing advice; it is the trial-reported rationale for why every escalation schedule in this class looks the way it does.

The glucagon arm, present in all three, is also the reason a modest heart-rate increase shows up across the class; this has been explicitly reported in the survodutide literature and is expected mechanistically wherever a glucagon receptor agonist is combined with GLP-1. ^[2] Retatrutide's dose-dependent dysesthesia (tingling or altered skin sensation) at higher doses appears, so far, to be a retatrutide-specific finding rather than a class effect, though this should be revisited as more mazdutide and survodutide safety data mature. ^[1] Retatrutide's full side-effect profile is covered in the retatrutide side effects guide.

Dosing and cadence: how the three compare

All three are once-weekly subcutaneous compounds studied with multi-week stepwise titration, which is the norm across this entire drug class. The specific numbers, however, do not translate across compounds.

The most important thing to understand about any dose column across this class is that milligram numbers are not comparable between different compounds. Potency per milligram differs by molecule, so a smaller number does not signal a weaker compound. What matters is each compound's own mean effect at its own top studied dose, which is the figure in the efficacy table earlier in this article. Retatrutide's pharmacokinetics, including its roughly six-day half-life and the four-to-five week window to reach steady state, are detailed in the half-life guide. The most common mistake with any compound in this class is reading the quiet first month as a failed protocol; levels are still climbing toward steady state, which is exactly why trial endpoints for all three compounds are reported at 24, 46, or 48 weeks rather than early.

Beyond the scale: liver fat across the three

Because all three compounds recruit the glucagon receptor, all three have reported some effect on liver fat, though the depth of that evidence differs sharply by compound.

Survodutide has the most direct evidence: its dedicated Phase 2 MASH (metabolic dysfunction-associated steatohepatitis) trial reported high rates of histological improvement in liver disease without worsening of fibrosis, measured by biopsy rather than imaging alone. ^[3] Retatrutide reported liver fat as a secondary endpoint in its obesity Phase 2 trial, showing large reductions by MRI-PDFF imaging alongside improvements in triglycerides and blood pressure. ^[1] Mazdutide's published liver-fat data are, as of this writing, less established in this draft's sources than the other two compounds, and should not be assumed to match either the survodutide biopsy program or retatrutide's imaging endpoint until confirmed.

Mechanistically, this pattern is coherent across all three: the glucagon receptor's effect on hepatic energy turnover and lipid handling is exactly where liver-fat changes would be expected to show up, regardless of which of the two other receptors (GIP, in retatrutide's case) rides alongside it.

Development stage: where each of the three sits in its pipeline

None of these three compounds is approved anywhere, but all three have moved out of early testing into larger, confirmatory programs.

Phase 2 establishes promise; Phase 3 is where a compound has to hold up in larger, longer, more rigorous testing across a broader population. All three are somewhere in that stage right now, which means the definitive long-term human safety and efficacy figures for any of the three are still being generated. For a research program, that is precisely what makes this comparison worth revisiting periodically rather than treating any one snapshot as final; mazdutide in particular is the compound in this trio whose published dataset is most likely to look meaningfully different within the next year or two as its Phase 3 program matures and more of it is confirmed in accessible, English-language sources.

Who each compound is right for

None of the three is universally "the best"; each sits at a different point on a map that trades receptor coverage, published depth of evidence, and geographic trial focus against each other.

Put plainly: retatrutide is still the maximal-effect, most mechanistically complete option of the three, with the deepest published dataset behind it. Survodutide is the dual agonist with the strongest Western, peer-reviewed evidence base and the clearest dedicated liver-disease program. Mazdutide is the newest entrant to a broad audience outside China, mechanistically similar to survodutide, and the one whose figures in this comparison most need a fresh check against primary sources before being treated as settled. If tirzepatide or semaglutide are also part of your comparison set, the retatrutide vs tirzepatide and semaglutide-vs-tirzepatide-vs-retatrutide breakdowns extend this same framework across the rest of the class.

The bottom line

Across three separate trials, retatrutide currently leads on published mean weight loss (24.2%), survodutide follows with the strongest dedicated liver-disease dataset among the two dual agonists (~18.7%, plus a biopsy-confirmed MASH program), and mazdutide rounds out the trio as a mechanistically similar dual agonist developed independently in China, with a shorter published trial window so far. ^{[1] [2] [3] [5]} The pattern across all three is consistent with the underlying receptor logic: adding GIP appears to add efficacy, and adding glucagon to any GLP-1 backbone appears to add a liver-fat effect. None of these is a head-to-head finding, and none of the three compounds is approved for human use. For the full retatrutide picture, see the complete retatrutide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies conducted independently for each compound; cross-compound comparisons in this article are drawn from separate trials, not head-to-head studies, and should be read as directional signals only. Survodutide, retatrutide, and mazdutide are all investigational and are not approved for human use.